This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Friday's Health Winners & Losers

Updated from 2:02 p.m. EDT

Takeover talk bolstered Bradley Pharmaceuticals (BDY), but health-care stocks were flat headed into the weekend.

Bradley rose $1.33, or 7.2%, to close at $19.87, after announcing Friday that it received an unspecified number of preliminary bids for the sale of the company. The company previously announced that it had hired Deutsche Bank as an advisor to help consider strategic alternatives.

Also up, Teva Pharmaceuticals (TEVA - Get Report) said that the FDA granted the company approval of its abbreviated new drug application to market the generic version of Novartis' (NVS - Get Report) Famvir treatment for genital herpes. Teva has been awarded a 180-day period of marketing exclusivity. Branded Famvir had annual sales of about $200 million in the U.S. for the 12 months ended June 30, according to the company.

Teva closed up 91 cents, or 2.2%, to $41.76. Novartis closed up 18 cents, or 0.3%, to $52.74. Teva is a component of the Amex Pharmaceutical Index, which was up 2.91 points, or 0.9%, to 339.03 on Friday.

Elsewhere, ImClone Systems (IMCL) said it opened enrollment for a phase II study on its candidate for advanced kidney cancer. It expects to enroll 36 patients whose disease has progressed during standard therapy or who have developed intolerance to those treatments. The study will evaluate the safety, efficacy and pharmacology of the drug.

However, the enrollment didn't help ImClone, which closed down 4 cents, or 0.1%, to $32.17.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BSX $18.40 0.00%
COR $48.46 0.00%
IMCL $3.00 0.00%
NVS $102.46 0.00%
TEVA $64.91 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs